Editas Medicine, Inc. (LON:0IFK)
London · Delayed Price · Currency is GBP · Price in USD 2.610
+0.011 (0.42%)
At close: Aug 5, 2025
Editas Medicine Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Gilmore O’Neill |
Contact Details
Address: 11 Hurley Street Cambridge, Delaware 02141 United States | |
| Phone | 617 401 9000 |
| Website | editasmedicine.com |
Stock Details
| Ticker Symbol | 0IFK |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US28106W1036 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gilmore O’Neill | Chief Executive Officer |
| Amy Parison | Chief Financial Officer |
| Cristi Barnett | Head of Investor Relations |